Stemgent Stemolecule A83-01

Code: 04-0014-base
  • $138.00
  • (Delivery from $45.00 )
Available   |   Usually dispatched within 24 hours
Prices apply to customers in North America only
Be the first to review Stemolecule A83-01. Write a review

A83-01 is a selective inhibitor of the transforming growth factor-β (TGFβ) type I receptor ALK5, the Activin/Nodal receptor ALK4, and the nodal receptor ALK71. This molecule is more potent than SB431542 in its inhibition of ALK4, 5, and 7, and only weakly inhibits ALK1, 2, 3, and 6. A83-01 inhibits the TGFβ-induced epithelial-to-mesenchymal transition (EMT) via the inhibition of Smad2 phosphorylation2.

Product Name

Stemolecule A83-01

Catalog Number


Pack Size

2 mg (Cat. No. 04-0014)

10 mg (Cat. No. 04-0014-10)

Alternate Name(s)

  • A-83-01
  • A 83-01
  • 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide

Chemical Formula


Molecular Weight


CAS Number



Greater than 98% by HPLC analysis


Pale yellow solid


A83-01 is soluble in DMSO at 50 mM.

Storage and Stability

Store powder at 4 °C protected from light. Information about the stability of Stemolecules in solution is largely not available. As a general guideline, we recommend that stock solution be freshly made and stored in aliquots at −20 °C. The effect of storage of stock solutions should be verified for each application.

Quality Control

The purity of A83-01 was determined by HPLC analysis. The accurate mass was determined by mass spectrometry. No acute cytotoxicity was observed in mouse embryonic stem cells following a 6 hour exposure to 1 nM - 100 µM A83-01.

  1. Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., and Imamura, T. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factorβ. Cancer Sci 96: 791-800 (2005).
  2. Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H., and Ding, S. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4: 16-19 (2009).

Additional Publications